JUNSHI BIO (01877): Tuoyi new indications and Junshida included in the national medical insurance directory.

JUNSHI BIO (01877) announces that recently, two new indications for the company's product Toripalimab Injection (trade name: Tuoyi, product code: JS001) and Avelumab Injection (trade name: Junshida, product code: JS002) have been successfully included in the "National Basic Medical Insurance, Maternity Insurance and Work-related Injury Insurance Drug List (2025)" (hereinafter referred to as the "National Medical Insurance List") Category B. The new version of the National Medical Insurance List will be officially implemented on January 1, 2026. As of the date of this announcement, four of the company's commercialized products, Tuoyi, Atezolizumab Injection (trade name: Junmaikang, product code: UBP1211), Deuterium Rimepitide Hydrobromide Tablets (trade name: Mindewei, product code: VV116/JT001), and Junshida, have all been included in the National Medical Insurance List. Tuoyi is the only anti-PD-1 monoclonal antibody drug in the directory approved for 12 indications for the treatment of kidney cancer, triple-negative breast cancer, and melanoma in mainland China. Junshida is newly included, being the only domestic PCSK9 targeting drug for statin-intolerant populations in the new version of the list.